NCT04667624View on ClinicalTrials.gov

Study to Evaluate the Safety and PK of LODIENT Tablet 80/2.5mg in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 29, 2020

Primary Completion Date

April 28, 2020

Study Completion Date

May 18, 2020

Conditions
Hypertension
Interventions
DRUG

Twynsta

Manufactured by Boehringer Ingelheim

DRUG

LodineT

•Manufactured by Hanlim Pharm. Co., Ltd, Seoul, Korea

Trial Locations (1)

430-720

Metro Hospital, Anyang

All Listed Sponsors
lead

Hanlim Pharm. Co., Ltd.

INDUSTRY

NCT04667624 - Study to Evaluate the Safety and PK of LODIENT Tablet 80/2.5mg in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter